Role of RAB32 on proliferation and migration of chronic myeloid leukemia K562 cells

doi:10.12092/j.issn.1009-2501.2019.12.001

Abstract

Abstract:

AIM: To investigate the effects of RAB32 on the proliferation and migration of chronic myeloid leukemia (CML) K562 cells. METHODS: The expression of RAB32 in newly diagnosed CML patients, healthy volunteers and K562 cell lines were assessed using Western blot and qRT-PCR. In addition, RAB32 gene expression was knocked down using RAB32-shRNA, and then the cell cycle variation of K562 cell was analyzed by flow cytometry. The expressions of cell proliferation-related genes (C-myc and CyclinD1) and migration-associated genes (MMP-3 and MMP-9) were assessed using Western blot and qRT-PCR. RESULTS:The results of Western blot and qRT-PCR showed that RAB32 were highly expressed in both CML patients and the K562 cell line (P＜0.01). Cell cycle analysis showed that compared with NC-shRNA group, the RAB32-shRNA group had decreased proportions of S-phase and G2/M-phase, especially S-phase cells (P＜0.01). The protein levels of C-myc, Cyclin D1, MMP-3 and MMP-9 were significantly down-regulated in K562 cells transfected with RAB32-shRNA compared with NC-shRNA group (P＜0.01). The mRNA levels of these four factors were also reduced in RAB32-shRNA group compared to NC-shRNA group (P＜0.01). CONCLUSION: Down-regulation of RAB32 could weaken K562 cell proliferation and migration.

Key words: RAB32, shRNA, human leukemia K562 cells, proliferation, migration

CLC Number:

R965.2

BAO Jing，LI Xiaofeng，ZHANG Hanshuo，XU Qingqing，MENG Xiaoming，HUANG Cheng，LI Jun. Role of RAB32 on proliferation and migration of chronic myeloid leukemia K562 cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1321-1327.

References

［1］Meenakshi S, Jiang XY, Brandwein JM, et al. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options［J］. Drug Discov Today, 2019, 24(7): 1355-1369.
［2］Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management［J］. Am J Hematol, 2014, 89(5): 547-556.
［3］Mendizabal AM, Younes N, Levine PH. Geographic and income variations in age at diagnosis and incidence of chronic myeloid leukemia［J］.Int J Hematol, 2016, 103(1):70-78.
［4］Koschmieder S, Vetrie D. Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options［J］. Semin Cancer Biol, 2018, 51:180-197.
［5］Shimada A . Hematological malignancies and molecular targeting therapy［J］. Eur J Pharmacol, 2019, 862:172641.
［6］Yaghmaie M, Yeung CC. Molecular mechanisms of resistance to tyrosine kinase inhibitors［J］. Curr Hematol Malig Rep, 2019,14(5):395-404.
［7］Kimura S. Molecular biology and treatment of CML［J］. Rinsho Ketsueki, 2017, 58(10):1920-1930.
［8］Shinde SR, Maddika S. Post translational modifications of Rab GTPases［J］. Small GTPases, 2018, 9(1-2):49-56.
［9］Prashar A, Schnettger L, Bernard EM, et al. RabGTPases in immunity and inflammation［J］. Front Cell Infect Microbiol, 2017, 7:435-446.
［10］Solano-Collado V, Rofe A, Spano S. Rab32 restriction of intracellular bacterial pathogens［J］. Small GTPases, 2018, 9(3): 216-223.
［11］Gao Y, Wilson GR, Stephenson SEM, et al. The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease［J］. Mov Disord, 2018, 33(2):196-207.
［12］Ortiz-Sandoval CG, Hughes SC, Dacks JB, et al. Interaction with the effector dynamin-related protein 1 (Drp1) is an ancient function of Rab32 subfamily proteins［J］. Cell Logist, 2014, 4(4): e986399.
［13］Rybnicek J, Samtleben S, Herrera-Cruz MS, et al. Expression of a T39N mutant Rab32 protein arrests mitochondria movement within neurites of differentiated SH-SY5Y cells［J］. Small GTPases, 2018, 7:1-4.
［14］Haile Y, Deng X, Ortiz-Sandoval C, et al. Rab32 connects ER stress to mitochondrial defects in multiple sclerosis［J］. J Neuroinflammation, 2017, 14 (1): 19-22.
［15］Radich JP, Deininger M, Abboud CN, et al. Chronic myeloid leukemia, version 12019, NCCN clinical practice guidelines in oncology［J］. J Natl Compr Canc Netw, 2018, 16(9):1108-1135.
［16］Fukuda M. Multiple Roles of VARP in endosomal trafficking: Rabs, retromer components and R-SNARE VAMP7 meet on VARP［J］. Traffic, 2016, 17(7):709-719.
［17］Li Z, Schulze RJ, Weller SG, et al. A novel Rab10-EHBP1-EHD2 complex essential for the autophagic engulfment of lipid droplets［J］. Sci Adv, 2016, 2(12): e1601470.
［18］Li C, Luo X, Zhao S, et al. COPI-TRAPPII activates Rab18 and regulates its lipid droplet association［J］. EMBO J, 2017, 36(4): 441-457.
［19］Scatena R. Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dedifferentiation［J］. Adv Exp Med Biol, 2012, 942: 287-308.
［20］Ryl T, Kuchen EE, Bell E, et al. Cell-cycle position of single MYC-driven cancer cells dictates their susceptibility to a chemotherapeutic drug［J］.Cell Syst,2017,5(3):237-250.
［21］Men LJ, Liu JZ, Chen HY, et al. Down regulation of G protein-coupled receptor 137 expression inhibits proliferation and promotes apoptosis in leukemia cells［J］.Cancer Cell Int,2018,18:13.
［22］Wells JM, Gaggar A, Blalock JE. MMP generated matrikines［J］. Matrix Biol, 2015, 44-46:122-129.
［23］Tan C, Qiao F, Wei P, et al. DIXDC1 activates the Wnt signaling pathway and promotes gastric cancer cell invasion and metastasis［J］. Mol Carcinog, 2016, 55(4): 397-408.
［24］Alaseem A, Alhazzani K, Dondapati P, et al. Matrix Metalloproteinases: A challenging paradigm of cancer management［J］. Semin Cancer Biol, 2019, 56:100-115.

[1]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[2]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[3]	DING Jiamin, WANG Youdi, ZHAO Xiali, JIANG Genfeng, CHEN Siwen, HONG Chengcheng, LI Shuqin, HU Weihua. Study on the treatment of thin endometrium with growth hormone and vitamin E [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 857-862.
[4]	SUI Yuxia, ZHUANG Jie, ZHUANG Min, HUANG Gui. Delicaflavone inhibits the invasion and migration of gefitinib-resistant lung cancer PC-9/GR cells by regulating epithelial-mesenchymal transition via PI3K/Akt/mTOR pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 614-621.
[5]	WANG Xinli, XU Xiaqing, FANG Hanbing, GUO Yuzhong. Study of TPA on enhancing the anti-tumor effects of cisplatin and reducing its renal toxicity [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 535-543.
[6]	LI Yanyan, FANG Xiaojie, YIN Xin, SUN Xi, RAO Chunhui. circZNF124 regulates the proliferation, migration and invasion of colorectal cancer SW620 cells by targeting miR-4262 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1231-1239.
[7]	LEI Jing, HE Ping, CAI Wenlin, ZHANG Yongzhe, ZHANG Beiru, LIU Dajun. Cordyceps sinensis extracts attenuates HBx-induced mesangial cell proliferation and extracellular matrix synthesis by suppression of the PI3K/Akt pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1247-1254.
[8]	JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi. AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
[9]	CHEN Linjun, CHEN Wenbin. Jolkinolide B inhibits the proliferation and metastasis of colon cancer cells via blocking PI3K/Akt/NF-κB pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 250-257.
[10]	PENG Fusheng, HUANG Xiaohui, LI Peng, TANG Jian'er. miR-34a inhibits proliferation of prostate cancer LNCaP cells by regulating androgen receptor gene [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 10-17.
[11]	WANG Xianghai, XING Min, LYU Tangfeng, LIU Hongbing, SONG Yong. Effects of knocking down long intergenic non-coding RNA 00467 on the prognosis of patients with lung adenocarcinoma and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 841-849.
[12]	HOU Bin, HUANG Weiping, YIN Zhongpu, HU Shousen. lncRNA PCAT19 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells by adsorbing miR-142-5p and regulating the expression of ING3 gene [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 721-727.
[13]	OU Jun, HOU Wenwen, TANG Jingwen, LI Jiaping, XU Qingyang. miR-106a regulates the proliferation of ovarian granulosa cells by targeting TIMP-2 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 527-532.
[14]	HUANG Kang, LI Ling, YE Qifa, PENG Guizhu. Expression of long non-coding RNA LINC00844 in hepatocellular carcinoma and its inhibiting effect on cell proliferation and migration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 366-372.
[15]	SHEN Cheng, YANG Nianzhao, WANG Minghai, WU Lisheng, ZHU Zhiqiang. Inhibiting RNA methylase NSUN2 reduce the invasion and migration of gastric cancer cell [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 380-386.